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mofetil (MMF) yielding four treatment arms: MMF + CYA (60),
MMF + FK (51), CSA (39), and FK (41). All patients were fol-
lowed for one year post-transplant. Using intent to treat or
crossover analysis outcomes were similar between FK- and CYA-
treated groups, allowing comparison of MMF patients (111) to
no-MMF patients (80). Costs (included: hospital, clinic, emer-
gency department, outpatient immunosuppression; excluded:
physician fees) were obtained using relative value units (RVUs,
microcosting), and wholesale acquisition prices. Ratios of cost-
to-charges (RCCs) for cost-estimate method comparisons were
obtained from a Medicare cost report. RESULTS: All treatment
arms had similar severity and chronology of rejection episodes.
In addition, there were no signiﬁcant differences between treat-
ment arms when actual costs (RVUs), or other cost-estimation
methods were used. Cost-center speciﬁc ratio of costs to charges
(RCCs) performed better than global hospital RCCs, but both
were signiﬁcantly different from, and underestimated, RVU
costs. Pharmacy appeared to be the reason why cost-center spe-
ciﬁc RCCs did not perform well. There were no signiﬁcant dif-
ferences between cost-center speciﬁc RCCs and RVU costs when
pharmacy RCCs were adjusted. CONCLUSIONS: There is not
a preferred immunosuppressive treatment substitute (MMF +
FK, MMF + CYA, FK, CYA) for the post-liver transplant popu-
lation at UCH. Traditional cost-estimate methods do not accu-
rately approximate costs. A pharmacy RCC adjustment may be
required for disease states that use signiﬁcant inpatient pharmacy
resources. Cost-center speciﬁc RCC method cost-estimates may
be improved with this methodology.
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OBJECTIVES: To assess responsiveness to change and construct
validity of the English Work Productivity and Activity Impair-
ment questionnaire for Gastro-Esophageal Reﬂux Disease
(WPAI-GERD). METHODS: The WPAI-GERD was used in a
clinical study in Canadian GERD patients with moderate or
severe symptoms treated with esomeprazole 40mg once daily for
4 weeks. Productivity variables obtained included GERD-speciﬁc
absence from work, reduced productivity while at work, and
reduced productivity while carrying out regular daily activities
other than work during the preceding week. RESULTS: The
analysis included 217 patients, of whom 71% (n = 153) were
employed. Before start of treatment, employed patients reported
an average of 0.9 hours absence from work and 14.0% reduced
work productivity (= 5.8 hours equivalent; % reduced produc-
tivity x hours actually worked), as well as 21.0% reduced pro-
ductivity in daily activities (all patients). After treatment, the
corresponding ﬁgures decreased to 0.3 hours, 3.0% (= 1.1 hours
equivalent) and 4.9%, respectively. Thus, the improvement (dif-
ference from start of treatment) in productivity was 0.6 hours (p
= 0.01) for absence from work, 11.0% units (p < 0.001) for
reduced work productivity (= 4.7 hours equivalent, p < 0.001)
and 16.1% units (p < 0.001) for reduced productivity in activi-
ties. This improvement translates into an avoided loss of work
productivity of 5.3 hours in total on a weekly basis per patient
employed. Cross-sectional correlation coefﬁcients between WPAI
variables and symptoms (range: 0.04–0.63), as well as health-
related quality of life (range: 0.02–0.65) supported cross-
sectional construct validity of the English WPAI-GERD. 
Corresponding change score correlations between WPAI vari-
ables and relevant symptoms were low (range: 0.10–0.23), which
would indicate poor longitudinal construct validity. CONCLU-
SIONS: Cross-sectional construct validity of the English WPAI-
GERD version was conﬁrmed and results indicated that the
WPAI-GERD is responsive to change. Although these results 
also indicated poor longitudinal construct validity, the overall
ﬁndings suggest that further study of the instrument remains
warranted.
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OBJECTIVES: To evaluate lost productivity in Inﬂammatory
Bowel Disease (IBD) patients from a large gastroenterology 
outpatient practice in an urban university hospital system.
METHODS: A self-administered survey was mailed to 614 IBD
patients. The survey included the WAII questionnaire (Work and
Activity Impairment from IBD), a modiﬁed version of the WPAI
(Work Productivity and Activity Impairment Questionnaire),
which measures lost productivity in the form of missed work
(absenteeism), impairment during work (presenteeism), and daily
activity impairment during the past year. Additional questions
pertaining to IBD disease severity, demographics, medical treat-
ment, and comorbid conditions were included. Multiple regres-
sion models were used to assess the impact of IBD severity, age,
gender, comorbidities, and disease type (Crohn’s Disease or
Ulcerative Colitis) on absenteeism, presenteeism, and activity
impairment. RESULTS: Of the 314 respondents (51.1%
response rate), 46.8% were female and 53.2% male (mean age
46.1 years). Respondents reported an average of 14.1% of sched-
uled work hours were lost due to absenteeism or disability.
Among respondents who missed at least some work in the past
year (n = 98; 31.2%), the mean number of hours missed was
56.4. On average respondents reported a 25.4% decrease in
workplace productivity (presenteeism), and reported a 30.4%
reduction in daily activity level due to IBD. Multiple regression
analysis revealed that IBD severity, age and anemia were the most
signiﬁcant predictors of absenteeism (p < 0.05). For presen-
teeism, IBD severity, anemia and hypercholesterolemia were 
signiﬁcant predictors (p < 0.05). Lastly, for daily activity 
impairment, IBD severity, female gender, and the comorbidities
of anemia, arthritis, hypercholesterolemia, depression and
anxiety were signiﬁcant predictors (p < 0.05). In all three models,
severity of IBD symptoms was the most important predictor of
lost productivity. CONCLUSIONS: The severity of IBD is a 
signiﬁcant determinant of productivity loss in the form of 
absenteeism from work, presenteeism at work, and daily 
activity impairment.
